AQUESTIVE THERAPEUTICS INC (AQST) Stock Price, Quote, News and Overview
NASDAQ:AQST - Nasdaq - US03843E1047 - Common Stock - Currency: USD
AQST Quote, Performance and Key Statistics
2.79
+0.03 (+1.09%)
The current stock price of AQST is 2.79 USD. In the past month the price increased by 15.29%. In the past year, price decreased by -9.71%.
AQST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.38 | 696.37B | ||
| JNJ | JOHNSON & JOHNSON | 15.35 | 371.06B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.9 | 291.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.08 | 214.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.16 | 209.49B | ||
| MRK | MERCK & CO. INC. | 9.75 | 191.17B | ||
| PFE | PFIZER INC | 6.94 | 126.36B | ||
| SNY | SANOFI-ADR | 13.1 | 122.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 94.53B | ||
| GSK | GSK PLC-SPON ADR | 6.72 | 74.10B | ||
| ZTS | ZOETIS INC | 26.46 | 71.04B | ||
| HLN | HALEON PLC-ADR | 22.38 | 48.43B |
Related stock screener links
About AQST
Company Profile
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Company Info
AQUESTIVE THERAPEUTICS INC
30 Technology Dr
WARREN NEW JERSEY 07059 US
CEO: Keith J. Kendall
Employees: 142
Phone: 19089411900
AQUESTIVE THERAPEUTICS INC / AQST FAQ
What is the stock price of AQUESTIVE THERAPEUTICS INC today?
The current stock price of AQST is 2.79 USD. The price increased by 1.09% in the last trading session.
What is the ticker symbol for AQUESTIVE THERAPEUTICS INC stock?
The exchange symbol of AQUESTIVE THERAPEUTICS INC is AQST and it is listed on the Nasdaq exchange.
On which exchange is AQST stock listed?
AQST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AQUESTIVE THERAPEUTICS INC stock?
15 analysts have analysed AQST and the average price target is 10.06 USD. This implies a price increase of 260.51% is expected in the next year compared to the current price of 2.79. Check the AQUESTIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AQUESTIVE THERAPEUTICS INC worth?
AQUESTIVE THERAPEUTICS INC (AQST) has a market capitalization of 277.10M USD. This makes AQST a Micro Cap stock.
How many employees does AQUESTIVE THERAPEUTICS INC have?
AQUESTIVE THERAPEUTICS INC (AQST) currently has 142 employees.
What are the support and resistance levels for AQUESTIVE THERAPEUTICS INC (AQST) stock?
AQUESTIVE THERAPEUTICS INC (AQST) has a support level at 2.74 and a resistance level at 2.8. Check the full technical report for a detailed analysis of AQST support and resistance levels.
Is AQUESTIVE THERAPEUTICS INC (AQST) expected to grow?
The Revenue of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -15.55% in the next year. Check the estimates tab for more information on the AQST EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AQUESTIVE THERAPEUTICS INC (AQST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AQST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AQST, evaluating the profitability, health, valuation and growth aspects
- AQUESTIVE THERAPEUTICS INC (AQST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AQUESTIVE THERAPEUTICS INC (AQST) Sales and EPS estimates to see what analysts future expectations are.
- AQUESTIVE THERAPEUTICS INC (AQST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AQUESTIVE THERAPEUTICS INC (AQST) Insider and Institutional Ownership to learn about the owners and their transactions.
- AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart to make your own analysis
- AQUESTIVE THERAPEUTICS INC (AQST) Latest news and press-releases to stay up to date.
Does AQUESTIVE THERAPEUTICS INC (AQST) stock pay dividends?
AQST does not pay a dividend.
When does AQUESTIVE THERAPEUTICS INC (AQST) report earnings?
AQUESTIVE THERAPEUTICS INC (AQST) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of AQUESTIVE THERAPEUTICS INC (AQST)?
AQUESTIVE THERAPEUTICS INC (AQST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
What is the Short Interest ratio of AQUESTIVE THERAPEUTICS INC (AQST) stock?
The outstanding short interest for AQUESTIVE THERAPEUTICS INC (AQST) is 10.62% of its float. Check the ownership tab for more information on the AQST short interest.
AQST Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AQST. When comparing the yearly performance of all stocks, AQST is a bad performer in the overall market: 65.55% of all stocks are doing better.
AQST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AQST. AQST has a bad profitability rating. Also its financial health evaluation is rather negative.
AQST Financial Highlights
Over the last trailing twelve months AQST reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS decreased by -44.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.52% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AQST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to AQST. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -31.42% and a revenue growth -15.55% for AQST